Hoffmann Chris, Gröner Benedikt, Bahutski Victor, Endepols Heike, Lindemeyer Johannes, Saniternik Sven, Drewes Birte, Timmer Marco, Gokhadze Otari, Brugger Melanie, Neumaier Felix, Neumaier Bernd, Zlatopolskiy Boris D
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Straße, Jülich, 52428, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Radiochemistry and Experimental Molecular Imaging, Kerpener Straße 62, 50937, Cologne, Germany.
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Straße, Jülich, 52428, Germany.
Eur J Med Chem. 2025 Dec 5;299:118103. doi: 10.1016/j.ejmech.2025.118103. Epub 2025 Aug 27.
Fibroblast activation protein (FAP) is almost exclusively expressed on cancer-associated stromal cells, making it a promising target for tumor imaging by positron emission tomography (PET). While Ga- or Al[F]F-labeled FAP inhibitors (FAPIs) have been characterized in detail, the potential advantages of FAPIs containing a covalently bound F-label remain largely unknown. The aim of the present work was to address this gap by comparing two FAPIs with a covalently bound F-label and the chelator-based radioligand Al[F]F-FAPI-42. The F-labeled FAPIs were prepared by direct (6-[F]F-FAPI) or indirect ([F]AFA-FAPI) radiofluorination, or by the Al[F]F chelation method (Al[F]F-FAPI-42), which afforded the tracers in activity yields of 11-57 % and with molar activities of 5-170 GBq/μmol. Cellular uptake studies revealed significantly higher accumulation of all three candidates in HT1080-FAP compared to HT1080-WT cells. 6-[F]F-FAPI and Al[F]F-FAPI-42 showed comparable FAP-selectivity and tumor uptake in mice inoculated with the two cell lines and rats bearing subcutaneous DSL-6A/C1 tumors, while no in vivo FAP-selectivity was observed for [F]AFA-FAPI. Al[F]F-FAPI-42 exhibited lower hepatobiliary excretion and faster clearance from FAP-negative tissues in the subcutaneous tumor models. In contrast, 6-[F]F-FAPI showed higher tumor uptake and better tumor retention in an intracerebral U87 glioma tumor model. When compared to the established glioma tracer [F]FET, both FAP-targeting tracers visualized intracerebral tumors with more than two-fold higher tumor-to-background ratios. In conclusion, while the chelator-based radioligand Al[F]F-FAPI-42 is well-suited for visualization of peripheral tumors, 6-[F]F-FAPI with a covalently bound F-label shows more favorable properties for brain tumor imaging.
成纤维细胞活化蛋白(FAP)几乎仅在癌症相关基质细胞上表达,这使其成为正电子发射断层扫描(PET)肿瘤成像的一个有前景的靶点。虽然镓或铝[F]F标记的FAP抑制剂(FAPIs)已得到详细表征,但含有共价结合F标记的FAPIs的潜在优势在很大程度上仍不为人知。本研究的目的是通过比较两种含有共价结合F标记的FAPIs和基于螯合剂的放射性配体铝[F]F-FAPI-42来填补这一空白。F标记的FAPIs通过直接(6-[F]F-FAPI)或间接([F]AFA-FAPI)放射性氟化或通过铝[F]F螯合方法(铝[F]F-FAPI-42)制备,其放射性示踪剂的活性产率为11-57%,摩尔活性为5-170 GBq/μmol。细胞摄取研究表明,与HT1080-WT细胞相比,所有三种候选物在HT1080-FAP中的积累显著更高。6-[F]F-FAPI和铝[F]F-FAPI-42在接种了这两种细胞系的小鼠和患有皮下DSL-6A/C1肿瘤的大鼠中显示出相当的FAP选择性和肿瘤摄取,而对于[F]AFA-FAPI未观察到体内FAP选择性。在皮下肿瘤模型中,铝[F]F-FAPI-42表现出较低的肝胆排泄和从FAP阴性组织中更快的清除。相比之下,在脑内U87胶质瘤肿瘤模型中,6-[F]F-FAPI显示出更高的肿瘤摄取和更好的肿瘤滞留。与已确立的胶质瘤示踪剂[F]FET相比,两种靶向FAP的示踪剂对脑内肿瘤的可视化肿瘤与背景比值高出两倍以上。总之,虽然基于螯合剂的放射性配体铝[F]F-FAPI-42非常适合外周肿瘤的可视化,但具有共价结合F标记的6-[F]F-FAPI在脑肿瘤成像方面显示出更有利的特性。